Phase 2 N=17 Treatment

LSA4 Protocol for the Treatment of Advanced Pediatric and Adolescent Non-Hodgkins Lymphoma

Non-Hodgkin's Lymphoma

Bottom Line

View on ClinicalTrials.gov: NCT00610883 ↗

Enrolled (actual)

Serious AEs

5.9%

Results posted

Jan 2016

Primary outcome: Primary: Complete Remission — 10 participants

Study Design & Population

Study type: Interventional
Phase: Phase 2
Interventions: LSA4, Cyclophosphamide, Methotrexate, Daunomycin, L-asparaginase, BCNU (Drug)
Age: Pediatric, Adult
Sex: All
Sponsor: Memorial Sloan Kettering Cancer Center
Primary completion: Dec 2008

Outcome Measures

Outcome	Result	p-value
PRIMARY Complete Remission	10	—

Summary

Non-Hodgin's lymphoma is curable in 76% of patients. In nonlymphoblastic lymphmas, cancer may return on average 3 months from beginning treatment and for lymphoblastic lymphomas, 6 months. To aggressively treat this cancer this study uses effective drugs in three parts: * Induction ends on day 19 * Consolidation ends on day 38 or 42 * Maintenance may include up to 6 cycles

Eligibility Criteria

Inclusion Criteria

Non-Hodgkin's Lymphoma stages III, IV, IVA with
T cell lymphomas, any primary site irrespective of LDH level
large cell lymphomas, any primary site irrespective of LDH level
B cell lymphomas, any primary site with initial LDH of less than 500

Exclusion Criteria

B cell lymphomas, any primary site with initial LDH of less than 500 and initial CNS or bone involvement

View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT00610883). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.